Sorry, last sentence was meant to be:My post is refers to the...

Sorry, last sentence was meant to be:

My post is refers to the publicly published data as it stands. If you look at just DMD, yeah may come across as "OH WOW THERE'S IMPROVEMENT" but looking at it on a broader perspective, many drugs in many diseases have similar or better data but commercially doesn't happen, simply because in HTA markets, you have a finite health budget (e.g Australia) and you can't fund relatively subpar medications. There's a better chance in private markets but it actually needs the clinical data to back it up, which was my original point. As I understand it, it doesn't exist yet and is what the upcoming trials are hoping to 'prove' but given the weak phase 2a data, doesn't look promising.In the past, FDA have approved drugs given orphan designation when their phase 2a/2b were so spectacular, they gave it provisional approval and I'm not sensing that (pun not intended) with ATL1102 as it stands.